Monte Rosa Therapeutics
Develops molecular glue degrader medicines across oncology, immunology, and inflammation.
$13.38
After-hours close+0.01 (+0.04%)
At close$13.38(−6.60%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 111.91%Insiders 1.05%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 84.48M · Float 59.76M · 70.7% free float
Institutions13F, as of Jun 30, 2026
202 holders · 94.54M shares · 31 new positions · 111 increased · 60 reduced · 26 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Price T Rowe Associates Inc /MD/ | 8.86M | 10.49% | +2.14M | Aug 14, 2026 |
| Nea Management Company, LLC | 7.69M | 9.11% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 6.84M | 8.10% | +1.21M | Aug 7, 2026 |
| TCG Crossover Management, LLC | 4.62M | 5.47% | 0 | Aug 14, 2026 |
| Vestal Point Capital, LP | 4.60M | 5.45% | +996.5K | Aug 14, 2026 |
| BVF Inc/IL | 4.46M | 5.28% | 0 | Aug 14, 2026 |
| Baker Bros. Advisors LP | 4.35M | 5.14% | 0 | Aug 14, 2026 |
| State Street Corp | 3.73M | 4.42% | +377.4K | Aug 7, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 9.99% | 8.88M | 13G | May 15, 2026 ↗ |
| Adam Goulburn | 8.10% | 6.51M | 13G | Apr 22, 2026 ↗ |
| Nea 17 GP, LLCincl. Paul Walker, Mohamad H. Makhzoumi +9 more | 7.90% | 6.69M | 13D | Jul 6, 2026 ↗ |
| T. Rowe Price Associates, Inc. | 7.50% | 4.64M | 13G | Nov 14, 2025 ↗ |
| BlackRock, Inc. | 6.30% | 3.84M | 13G | Feb 4, 2025 ↗ |
| Suvretta Capital Management, LLC | 5.50% | 3.36M | 13G | Apr 16, 2025 ↗ |
| Vestal Point Capital, LP | 5.40% | 4.60M | 13G | Aug 14, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Markus Warmuth | director, officer: President & CEO | 585.0K | 0.69% | Jul 17, 2026 |
| Sharon Townson | officer: Chief Scientific Officer | 67.8K | 0.08% | Jul 7, 2026 |
| Jennifer Champoux | officer: Chief Operating Officer | 62.4K | 0.07% | Jul 16, 2026 |
| Filip Janku | officer: Chief Medical Officer | 60.6K | 0.07% | Jul 1, 2026 |
| Philip Nickson | officer: Chief Business & Legal Officer | 55.0K | 0.07% | Apr 10, 2026 |
| Matthew Bowen | officer: Principal Accounting Officer | 25.9K | 0.03% | Apr 7, 2026 |
| Edmund Dunn | officer: Principal Accounting Officer | 22.6K | 0.03% | Mar 5, 2026 |
| Chandra P. Leo | director | 10.0K | 0.01% | Mar 25, 2025 |
13 ten-percent owners hold 38.13M shares by Form 4, outside the officers-and-directors figure above · 3 people have not refiled in the last 18 months (4.67M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 16, 2026 | Markus Warmuthdirector, officer: President & CEO | Sale | 9,500 | $23.18 | 585,038 |
| Jul 15, 2026 | Jennifer Champouxofficer: Chief Operating Officer | Sale | 4,351 | $23.38 | 62,371 |
| Jul 6, 2026 | Sharon Townsonofficer: Chief Scientific Officer | Sale · 2 lots | 6,000 | $23.31 | 67,845 |
| Jun 30, 2026 | Filip Jankuofficer: Chief Medical Officer | Sale | 5,407 | $24.50 | 60,612 |
| Jun 29, 2026 | Anthony M. Manningdirector | Sale | 10,000 | $23.11 | 0 |
| Jun 29, 2026 | Filip Jankuofficer: Chief Medical Officer | Sale | 6,000 | $22.95 | 59,992 |
| Jun 23, 2026 | Sharon Townsonofficer: Chief Scientific Officer | Sale | 3,000 | $20.00 | 67,845 |
| Jun 23, 2026 | Jennifer Champouxofficer: Chief Operating Officer | Sale | 2,175 | $20.00 | 62,371 |
| Jun 24, 2026 | Filip Jankuofficer: Chief Medical Officer | Sale | 30,000 | $21.42 | 59,992 |
| Jun 23, 2026 | Filip Jankuofficer: Chief Medical Officer | Sale | 11,845 | $20.22 | 59,992 |
CongressHouse and Senate disclosures
Not reported.